BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ribeiro de Souza A, Reig M, Bruix J. Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. Expert Opinion on Pharmacotherapy 2016;17:1923-36. [DOI: 10.1080/14656566.2016.1225722] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Lan J, Wang N, Huang L, Liu Y, Ma X, Lou H, Chen C, Feng Y, Pan W. Design and synthesis of novel tetrandrine derivatives as potential anti-tumor agents against human hepatocellular carcinoma. European Journal of Medicinal Chemistry 2017;127:554-66. [DOI: 10.1016/j.ejmech.2017.01.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
2 Guo YX. Hepatocellular carcinoma with right atrial tumor thrombus. Z Gastroenterol 2021;59:153-61. [PMID: 33152793 DOI: 10.1055/a-1275-3780] [Reference Citation Analysis]
3 Bruix J, Cheng AL, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. J Hepatol. 2017;67:999-1008. [PMID: 28687477 DOI: 10.1016/j.jhep.2017.06.026] [Cited by in Crossref: 234] [Cited by in F6Publishing: 234] [Article Influence: 46.8] [Reference Citation Analysis]
4 Dutta R, Mahato RI. Recent advances in hepatocellular carcinoma therapy. Pharmacol Ther. 2017;173:106-117. [PMID: 28174094 DOI: 10.1016/j.pharmthera.2017.02.010] [Cited by in Crossref: 120] [Cited by in F6Publishing: 124] [Article Influence: 24.0] [Reference Citation Analysis]
5 Du B, Zhang P, Tan Z, Xu J. MiR-1202 suppresses hepatocellular carcinoma cells migration and invasion by targeting cyclin dependent kinase 14. Biomed Pharmacother 2017;96:1246-52. [PMID: 29217161 DOI: 10.1016/j.biopha.2017.11.090] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
6 Cucchetti A, Piscaglia F, Pinna AD, Djulbegovic B, Mazzotti F, Bolondi L. Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials. Liver Cancer. 2017;6:337-348. [PMID: 29234637 DOI: 10.1159/000481314] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
7 Bieniek A, Wiśniewski M, Czarnecka J, Wierzbicki J, Ziętek M, Nowacki M, Grzanka D, Kloskowski T, Roszek K. Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma Treatment. Int J Mol Sci 2021;22:11161. [PMID: 34681820 DOI: 10.3390/ijms222011161] [Reference Citation Analysis]
8 Hou C, Guo D, Yu X, Wang S, Liu T. TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib. Biomed Pharmacother 2020;126:109862. [PMID: 32120157 DOI: 10.1016/j.biopha.2020.109862] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
9 Karakuş S, Tok F, Türk S, Salva E, Tatar G, Taskın-tok T, Kocyigit-kaymakcıoglu B. Synthesis, anticancer activity and ADMET studies of N-(5-methyl-1,3,4-thiadiazol-2-yl)-4-[(3-substituted)ureido/thioureido] benzenesulfonamide derivatives. Phosphorus, Sulfur, and Silicon and the Related Elements 2018;193:528-34. [DOI: 10.1080/10426507.2018.1452924] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]